Kim N, Vishwanath D, Xi Z, Nagaraja O, Swamynayaka A, Kumar Harish K
Molecules. 2023; 28(8).
PMID: 37110684
PMC: 10142175.
DOI: 10.3390/molecules28083450.
Nalinratana N, Suriya U, Laprasert C, Wisidsri N, Poldorn P, Rungrotmongkol T
Sci Rep. 2023; 13(1):3558.
PMID: 36864126
PMC: 9981598.
DOI: 10.1038/s41598-023-30475-5.
Bamou F, Le T, Tayeb B, Tahaei S, Minorics R, Zupko I
ChemistryOpen. 2022; 11(10):e202200169.
PMID: 36200514
PMC: 9535514.
DOI: 10.1002/open.202200169.
Duong M, Lee J, Ahn H
Comput Struct Biotechnol J. 2020; 18:1440-1457.
PMID: 32637042
PMC: 7327381.
DOI: 10.1016/j.csbj.2020.06.013.
Xu M, Ye Y, Ye Z, Xu S, Liu W, Xu J
Haematologica. 2019; 105(3):674-686.
PMID: 31289206
PMC: 7049331.
DOI: 10.3324/haematol.2019.215939.
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
Fearon D, Westwood I, van Montfort R, Bayliss R, Jones K, Bavetsias V
Bioorg Med Chem. 2018; 26(11):3021-3029.
PMID: 29764757
PMC: 6008489.
DOI: 10.1016/j.bmc.2018.04.033.
Pyridopyrimidinone Derivatives as Potent and Selective c-Jun N-Terminal Kinase (JNK) Inhibitors.
Zheng K, Park C, Iqbal S, Hernandez P, Park H, LoGrasso P
ACS Med Chem Lett. 2015; 6(4):413-8.
PMID: 25893042
PMC: 4394340.
DOI: 10.1021/ml500474d.
Anthrapyrazolone analogues intercept inflammatory JNK signals to moderate endotoxin induced septic shock.
Prasad K, Trinath J, Biswas A, Sekar K, Balaji K, Guru Row T
Sci Rep. 2014; 4:7214.
PMID: 25428720
PMC: 4245532.
DOI: 10.1038/srep07214.
Exploring conformational search protocols for ligand-based virtual screening and 3-D QSAR modeling.
Cappel D, Dixon S, Sherman W, Duan J
J Comput Aided Mol Des. 2014; 29(2):165-82.
PMID: 25408244
DOI: 10.1007/s10822-014-9813-4.
Design and synthesis of highly potent and isoform selective JNK3 inhibitors: SAR studies on aminopyrazole derivatives.
Zheng K, Iqbal S, Hernandez P, Park H, LoGrasso P, Feng Y
J Med Chem. 2014; 57(23):10013-30.
PMID: 25393557
PMC: 4266361.
DOI: 10.1021/jm501256y.
Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors.
Lawrence H, Martin M, Luo Y, Pireddu R, Yang H, Gevariya H
J Med Chem. 2012; 55(17):7392-7416.
PMID: 22803810
PMC: 4429609.
DOI: 10.1021/jm300334d.
Posttranslational modification of vesicular stomatitis virus glycoprotein, but not JNK inhibition, is the antiviral mechanism of SP600125.
Marozin S, Altomonte J, Apfel S, Dinh P, De Toni E, Rizzani A
J Virol. 2012; 86(9):4844-55.
PMID: 22345438
PMC: 3347359.
DOI: 10.1128/JVI.06649-11.
2D QSAR Studies of Several Potent Aminopyridine, Anilinopyrimidine and Pyridine Carboxamide-based JNK Inhibitors.
Sharma S, Bagchi B, Mukhopadhyay S, Bothra A
Indian J Pharm Sci. 2012; 73(2):165-70.
PMID: 22303059
PMC: 3267300.
DOI: 10.4103/0250-474x.91584.
Analysis of conditions affecting auto-phosphorylation of human kinases during expression in bacteria.
Shrestha A, Hamilton G, ONeill E, Knapp S, Elkins J
Protein Expr Purif. 2011; 81(1):136-143.
PMID: 21985771
PMC: 3445812.
DOI: 10.1016/j.pep.2011.09.012.
Synthesis and SAR of piperazine amides as novel c-jun N-terminal kinase (JNK) inhibitors.
Shin Y, Chen W, Habel J, Duckett D, Ling Y, Koenig M
Bioorg Med Chem Lett. 2009; 19(12):3344-7.
PMID: 19433357
PMC: 2737472.
DOI: 10.1016/j.bmcl.2009.03.086.
Inhibitors of c-Jun N-terminal kinases: JuNK no more?.
Bogoyevitch M, Arthur P
Biochim Biophys Acta. 2007; 1784(1):76-93.
PMID: 17964301
PMC: 7185448.
DOI: 10.1016/j.bbapap.2007.09.013.
